Mesenchymal stem cells as delivery systems for cancer and leukemia gene therapy
DOI:
10.1200/jco.2004.22.90140.3194
Publication Date:
2017-04-05T03:17:42Z
AUTHORS (10)
ABSTRACT
3194 Background: We previously demonstrated that intravenously (IV) injected bone marrow-derived mesenchymal stem cells (MSC) integrate into solid tumors as stromal fibroblasts and proliferate selectively in situ. here propose a novel cancer therapy concept based on the intratumoral drug production by gene-modified MSC. Methods: MSC were transduced with adeno (AdV)- or adeno-associated (AAV) virus carrying marker- therapeutic genes. Gene-modified IV mice xenografts. Results: found only tumors, where they not normal tissues. producing human interferon-beta (IFNβ-MSC) directly inhibited growth of metastatic A375 melanoma MDA 231 breast carcinoma following injection (p=0.0073), while recombinant IFNβ protein subcutaneously (SC) did (p=0.14). IFNβ-MSC doubled survival tumor-bearing (p=0.001) SC was ineffective (p=0.021 vs p=0.4). Intraperitoneal (IP) injections ovarian carcinomas their (SKOV-3) cured 70% OVAR-3 mice. IP administration replication competent oncolytic adenovirus prolonged survival. carotid artery (IA) gliomas proliferated gliomas, brain Intratumoral vivo significantly tumor growth. In model chronic myelogenous leukemia blast crisis (KBM5), interferon α (IFNα) produced induced regressions The differentiation-associated gene 7 (MDA7) MSC, preferentially Gleevec resistant KBM5 CML cells. Conclusions: Results suggest grow inhibit leukemias, cancers. Tumor inhibition required spatial proximity to malignant findings proteins replicating have potent anti-tumor effects when situ use tumor-selective delivery systems. No significant financial relationships disclose.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....